Parkinsons Disease Home > Azilect and Pregnancy
In animal studies on Azilect (rasagiline mesylate) and pregnancy, the medication decreased offspring survival and body weight when given to pregnant rats. Since animals do not always respond to medicines the same way that humans do, however, Azilect can be prescribed during pregnancy if the benefits outweigh any possible risks. If you are taking Azilect and pregnancy occurs, notify your healthcare provider immediately.
Azilect® (rasagiline mesylate) is a prescription medication approved for Parkinson's disease treatment. Based on animal studies, Azilect may not be safe for use during pregnancy, although the full risks to humans are not currently known.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that appear to cause harm to the fetus in animal studies but have not been studied in pregnant humans. Also, medicines that have not been studied in any pregnant women or animals are automatically given a default pregnancy Category C rating.
When given to pregnant rats, Azilect decreased offspring survival and offspring body weight.
It is important to keep in mind that animals do not always respond to medicines in the same way that humans do. Therefore, a pregnancy Category C medicine may be given to a pregnant woman if her healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child.
If you are pregnant or are thinking about becoming pregnant, let your healthcare provider know. He or she will consider the benefits and risks of taking Azilect during pregnancy before making a recommendation in your particular situation.